bit.ly With millions of people hospitalized each year due to heart failure, results from a pivotal clinical trial show that an implantable pulmonary artery pressure device in patients with moderate heart failure results in significant reductions in hospitalizations and re-admissions for those patients. The study, published Feb. 10 in the Lancet, represents the first major breakthrough in heart failure management in the past decade. “For the first time, the device allows us to directly manage a patient’s pulmonary pressures, rather than managing symptoms or weight gain,” says Dr. William Abraham, director of the division of cardiovascular medicine at The Ohio State University Medical Center and the study’s national co-principal investigator. Researchers found that the wireless monitor resulted in reductions in pulmonary artery pressures, increases in days alive and out of the hospital, and improved quality of life. The study also found that heart failure management using the pulmonary artery pressure monitoring system resulted in a 30 percent reduction in heart failure hospitalizations at six months and a 39 percent reduction in yearly heart failure hospitalization rates. Improvements cited in the study were judged to be cost-effective, with costs less than 000.00 per quality-adjusted life year gained, an amount much less than widely-recognized cost-effectiveness benchmarks such as renal dialysis. Despite current drug and device therapies, heart failure rates remain …
Posts Related to Wireless Monitor Reduces Heart Failure Hospitalizations
All Identi.ca content and data are available under the